NASDAQ:GLPG - GALAPAGOS NV/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $118.61 +1.58 (+1.35 %) (As of 05/22/2019 02:37 PM ET)Previous Close$117.03Today's Range$118.43 - $119.6552-Week Range$85.00 - $125.48Volume578 shsAverage Volume109,532 shsMarket Capitalization$6.08 billionP/E RatioN/ADividend YieldN/ABeta1.63 ProfileAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106; and Evotec AG for the novel target for fibrosis and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium. Receive GLPG News and Ratings via Email Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLPG Previous Symbol CUSIPN/A CIK1421876 Webhttp://www.glpg.com/ Phone321-534-2900Debt Debt-to-Equity Ratio0.02 Current Ratio6.31 Quick Ratio6.31Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$375.54 million Price / Sales16.18 Cash FlowN/A Price / Cash FlowN/A Book Value$26.06 per share Price / Book4.55Profitability EPS (Most Recent Fiscal Year)($0.66) Net Income$-34,560,000.00 Net Margins-13.24% Return on Equity-3.60% Return on Assets-2.91%Miscellaneous EmployeesN/A Outstanding Shares51,235,000Market Cap$6.08 billion Next Earnings Date8/1/2019 (Estimated) OptionableOptionable GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions What is GALAPAGOS NV/S's stock symbol? GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG." When is GALAPAGOS NV/S's next earnings date? GALAPAGOS NV/S is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for GALAPAGOS NV/S. What price target have analysts set for GLPG? 13 brokerages have issued 1 year price targets for GALAPAGOS NV/S's shares. Their forecasts range from $90.00 to $157.00. On average, they anticipate GALAPAGOS NV/S's share price to reach $129.10 in the next twelve months. This suggests a possible upside of 8.8% from the stock's current price. View Analyst Price Targets for GALAPAGOS NV/S. What is the consensus analysts' recommendation for GALAPAGOS NV/S? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GALAPAGOS NV/S. What are Wall Street analysts saying about GALAPAGOS NV/S stock? Here are some recent quotes from research analysts about GALAPAGOS NV/S stock: 1. Cantor Fitzgerald analysts commented, "Our Galapagos thesis: We think that 2019 is the year filgotinib will differentiate itself among the JAKs. We reiterate our Overweight and price target of $130. We expect key Phase 3 data from filgotinib in studies called FINCH 1 and 3 in 1Q19. We think that these data may reveal that filgotinib has an attractive risk/benefit profile among the JAK inhibitors. Section may be found on pages 4 – 5.We value Galapagos shares on a probability-adjusted DCF." (5/2/2019) 2. According to Zacks Investment Research, "Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. " (3/1/2019) Has GALAPAGOS NV/S been receiving favorable news coverage? Media stories about GLPG stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. GALAPAGOS NV/S earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of GALAPAGOS NV/S's key competitors? Some companies that are related to GALAPAGOS NV/S include BioMarin Pharmaceutical (BMRN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Marina Biotech (MRNA) and Alnylam Pharmaceuticals (ALNY). What other stocks do shareholders of GALAPAGOS NV/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other GALAPAGOS NV/S investors own include Gilead Sciences (GILD), CELYAD SA/ADR (CYAD), argenx (ARGX), Intercept Pharmaceuticals (ICPT), Celgene (CELG), Collegium Pharmaceutical (COLL), Pharming Group (PHGUF), NVIDIA (NVDA), Sociedad Quimica y Minera de Chile (SQM) and Glencore (GLEN). Who are GALAPAGOS NV/S's key executives? GALAPAGOS NV/S's management team includes the folowing people: Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)Mr. Bart Filius MBA, CFO & COO (Age 49)Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. CommunicationsDr. Andre Hoekema, Chief Bus. Officer (Age 62) When did GALAPAGOS NV/S IPO? (GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. Who are GALAPAGOS NV/S's major shareholders? GALAPAGOS NV/S's stock is owned by a number of of retail and institutional investors. Top institutional investors include Federated Investors Inc. PA (3.28%), FMR LLC (0.98%), Wellington Management Group LLP (0.66%), BlackRock Inc. (0.57%), Alps Advisors Inc. (0.17%) and Peregrine Capital Management LLC (0.17%). Which major investors are selling GALAPAGOS NV/S stock? GLPG stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, BlackRock Inc., Wellington Management Group LLP, Atika Capital Management LLC, Renaissance Technologies LLC, Victory Capital Management Inc., Morgan Stanley and Peregrine Capital Management LLC. Which major investors are buying GALAPAGOS NV/S stock? GLPG stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Alps Advisors Inc., SEI Investments Co, Eqis Capital Management Inc., JPMorgan Chase & Co., Ellington Management Group LLC and DekaBank Deutsche Girozentrale. How do I buy shares of GALAPAGOS NV/S? Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is GALAPAGOS NV/S's stock price today? One share of GLPG stock can currently be purchased for approximately $118.61. How big of a company is GALAPAGOS NV/S? GALAPAGOS NV/S has a market capitalization of $6.08 billion and generates $375.54 million in revenue each year. The biotechnology company earns $-34,560,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. What is GALAPAGOS NV/S's official website? The official website for GALAPAGOS NV/S is http://www.glpg.com/. How can I contact GALAPAGOS NV/S? GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected] MarketBeat Community Rating for GALAPAGOS NV/S (NASDAQ GLPG)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 346 (Vote Outperform)Underperform Votes: 300 (Vote Underperform)Total Votes: 646MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote "Outperform" if you believe GLPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Municipal Bonds Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.